Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

LAK1 antigen defines two distinct subsets among human tumour infiltrating lymphocytes.

British journal of cancer - 1 Nov 1990

Ferrarini M, Ferrero E, Fortis C, Poggi A, Zocchi M R

Abstract excerpt

Both lymphokine activated killer (LAK) cells and specific cytotoxic T lymphocytes appear to play a role in tumour immunity. Tumour infiltrating lymphocytes (TIL) which display a CD56+ phenotype (both CD3+ and CD3-) are also likely to possess anti-tumour activity. We have previously described a 120 kDa surface antigen, termed LAK1, expressed on a subset of human peripheral blood lymphocytes (20-50%) with both NK...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Differentiation, T-Lymphocyte
Share to Antigens, Surface

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to CD3 Complex

Share to Killer Cells, Lymphokine-Activated

Share to Neoplasms

Share to Phenotype

Share to Receptors, Antigen, T-Cell

Share to T-Lymphocyte Subsets

Source

Open in PubMed Open full text

Identifiers

PMID: 1700922
DOI: 10.1038/bjc.1990.372
PMCID: PMC1971538

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

LAK1 antigen defines two distinct subsets among human tumour infiltrating lymphocytes.PMID 1700922Read ↗

Cytolytic effector cells against human tumors: distinguishing phenotype and function.Semantic proximity Read ↗

A novel role for MHC class II antigens: evidence implicating a protective effect on tumour cells against cytotoxicity by NK and LAK cells.Semantic proximity Read ↗

Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma.Semantic proximity Read ↗

Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.Semantic proximity Read ↗

Increased frequency of CD4+ cells expressing CD161 in cancer patients.Semantic proximity Read ↗

Development of four donor-specific phenotypes in human long-term lymphokine-activated killer cell cultures.Semantic proximity Read ↗

High release of tumor necrosis factor alpha, interferon gamma and interleukin-6 by adherent lymphokine-activated killer cells phenotypically derived from T cells.Semantic proximity Read ↗

Differential lysis of tumor target cells displayed by lymphokine activated killer (LAK) cell clones.Semantic proximity Read ↗

Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: II. Characterization of cells cultured ex vivo and their contribution to the in vivo immunomodulation.Semantic proximity Read ↗

Human spleen and peripheral blood lymphocytes activated by interleukin-2 have similar phenotypic and functional characteristics.Semantic proximity Read ↗

Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma.Semantic proximity Read ↗

Lymphokine-activated killer (LAK) cells discriminate between Epstein-Barr virus (EBV)-positive Burkitt's lymphoma cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.